Adrb1 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The ADRB1 gene (Adrenoceptor Beta 1) encodes the β1-adrenergic receptor, a G-protein coupled receptor that responds to catecholamines epinephrine and norepinephrine. In the brain, β1-adrenergic receptors are involved in arousal, attention, learning, and memory formation, and are implicated in neurodegenerative diseases.
Key points:
Beta-1 Adrenergic Receptor
| Symbol | ADRB1 |
| Full Name | Beta-1 Adrenergic Receptor |
| Chromosome | 10q25.3 |
| NCBI Gene ID | 153 |
| OMIM | 109630 |
| Ensembl | ENSG00000143578 |
| UniProt | P08588 |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, Heart Failure, Hypertension, Depression |
The ADRB1 gene encodes the beta-1 adrenergic receptor (β1-AR), a G-protein coupled receptor that couples to Gs proteins, stimulating adenylyl cyclase and increasing cAMP. This receptor is the primary receptor mediating cardiac sympathetic responses.
β1-AR activation triggers:
β1-adrenergic signaling in the brain modulates attention, memory formation, and arousal. Dysregulation contributes to cognitive deficits in AD. Beta-blockers may have protective effects.
Cardiac sympathetic denervation is a hallmark of PD. β1- receptor function is affected, contributing to orthostatic hypotension.
β1-AR is the primary therapeutic target for heart failure and hypertension. Beta-blockers (metoprolol, atenolol, carvedilol) are cornerstone treatments.
β1-AR sensitivity may be altered in depression. Some antidepressants affect β-adrenergic signaling.
β1-AR is expressed in:
Clinical uses: hypertension, heart failure, arrhythmias, angina, anxiety
[1] Lefkowitz RJ, et al. (2000). Historical review: Molecular cloning of beta-adrenergic receptors. Mol Pharmacol. PMID:10860935.
[2] Brodde OE. (2008). Beta-1 and beta-2 adrenergic receptors. Pharmacol Ther. PMID:18062921.
The study of Adrb1 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Lefkowitz RJ, et al. Historical review: the discovery of beta-adrenergic receptors. Mol Pharmacol. 2000;57(2):265-268. PMID:10860935.
[2] Brodde OE. Beta-1 and beta-2 adrenergic receptors: distribution and function in the immune system. Pharmacol Ther. 2008;118(1):1-35. PMID:18062921.
The ADRB1 gene is located on chromosome 10q26.12 and spans approximately 2.4 kb. It consists of a single exon encoding a 477-amino acid G-protein coupled receptor. The promoter region contains binding sites for transcription factors including CRE, Sp1, and AP-1 elements that regulate expression in cardiac and neuronal tissues.
ADRB1 primarily couples to Gs proteins, activating adenylyl cyclase and increasing cAMP levels. Key downstream signaling includes PKA activation and phosphorylation of L-type calcium channels, phosphorylation of troponin I and phospholamban, activation of MAPK pathways (ERK1/2), and beta-arrestin mediated signaling. In the brain, beta-1 adrenergic receptors play critical roles in synaptic plasticity and memory consolidation, attention and arousal regulation, stress response modulation, and regulation of neuroinflammation.
Beta-1 adrenergic receptors are major drug targets. Beta-blockers including Metoprolol, Atenolol, and Bisoprolol are used for cardiac therapy. Novel antagonists are under development for CNS indications. In neurodegeneration, beta-1 modulation may reduce neuroinflammation, modulate amyloid-beta effects, protect against ischemic damage, and influence autonomic dysfunction in Parkinson's disease.
Animal models include knockout mice with cardiac abnormalities and altered stress responses, conditional knockouts for tissue-specific deletion studies, and transgenic overexpression models in cardiac and neuronal tissues.
Current research focuses on developing brain-penetrant beta-1 antagonists for neurodegeneration, understanding beta-1/beta-2 receptor crosstalk, the role in glymphatic system and sleep, and beta-1 receptor imaging ligands.